Rafael Pharmaceuticals (Formerly known as Cornerstone Pharmaceuticals, Inc.)

122 articles about Rafael Pharmaceuticals (Formerly known as Cornerstone Pharmaceuticals, Inc.)

• Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

  7/21/2020

  Rafael Pharmaceuticals, Inc. announced that it has crossed the midpoint to its first interim analysis in enrollment for its pivotal Phase 3 clinical trial of CPI-613® for relapsed or refractory acute myeloid leukemia. The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone in older patients.

• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

• Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

  5/26/2020

  Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the positive results of a single-arm, open-label, Phase 1 study of CPI-613 ®  (devimistat) with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer, will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Vi

• Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models

  5/7/2020

  Company advances mission to combat AML, as this research comes on the heels of its Phase 3 trial, actively enrolling globally

• Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer

  5/5/2020

  Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has entered into a research collaboration with Roswell Park Comprehensive Cancer Center . Through this collaboration, researchers will evaluate the effects of CPI-613® (devimistat) with or without chemotherapy agents, including oxaliplatin/cisplatin/5-FU/carboplatin/taxol, on esophageal cancer

• 

  Clinical Catch-Up: April 27-May 1

  5/4/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.

• MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia

  4/28/2020

  Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic

• 

  Clinical Catch-Up: April 20-24

  4/27/2020

  Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.

• Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

  4/23/2020

  Patient enrollment will begin only once local health officials determine that it is safe, in light of the COVID-19 pandemic

• 

  As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

  4/17/2020

  Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have.
• 

  Clinical Catch-Up: March 23-27

  3/30/2020

  Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.

• Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

  3/24/2020

  COVID-19 task force established to support enrolled patients Participating medical centers implemented safety measures and currently enrolling patients

• Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results

  3/5/2020

  Rafael Holdings, Inc. reported revenue of $1.2 million and a loss per diluted share of $0.08 for the fiscal quarter ended January 31, 2020.

• Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance OfficerDr. Sehgal joins Rafael Pharmaceuticals to lead the growth of regulatory affairs

  3/3/2020

  Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer. 

• 

  Clinical Catch-Up: Jan 20-24

  1/27/2020

  The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look.

• Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

  1/21/2020

  Clinical trial further bolsters company’s pipeline in and focus on gastrointestinal cancers

• 

  Clinical Catch-Up: January 13-17

  1/20/2020

  There were plenty of clinical trial announcements this week. Here's a look.

• Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

  1/14/2020

  Clinical trial using devimistat in combination with FOLFIRINOX as first-line treatment has enrolled more than 250 patients ahead of scheduled timeline

• Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

  1/13/2020

  President and CEO Sanjeev Luther to discuss the status of clinical trials for lead compound CPI-613® (devimistat) and provide update on drug development pipeline

• 

  Clinical Catch-Up: December 2-5

  12/9/2019

  It was, as usual, a pretty busy week in clinical trial news. Here’s a look.